Infliximab, adalimumab, certolizumab pegol ( DrugBank: Adalimumab, Infliximab, Certolizumab pegol )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	1
97	Ulcerative colitis	1

96. Crohn disease

---

Clinical trials : 2,442 /  Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02073526 (ClinicalTrials.gov)	May 2013	9/1/2014	Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease	Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease	Inflammatory Bowel Disease;Crohn's Disease;Ulcerative Colitis	Drug: Infliximab, adalimumab, certolizumab pegol	Oslo University Hospital	NULL	Completed	18 Years	N/A	Both	1230	N/A	Norway

97. Ulcerative colitis

---

Clinical trials : 2,630 /  Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02073526 (ClinicalTrials.gov)	May 2013	9/1/2014	Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease	Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease	Inflammatory Bowel Disease;Crohn's Disease;Ulcerative Colitis	Drug: Infliximab, adalimumab, certolizumab pegol	Oslo University Hospital	NULL	Completed	18 Years	N/A	Both	1230	N/A	Norway